Aktienanalyse wird geladen …
TECH · NASDAQ · Biotechnology · USA
72,57 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1,22 Mrd. | 181,84 Mio. | 1,16 $ | 157,01 Mio. | 0,6 Mio · 0,4 % | 3,3 Mio · 2,1 % | 65,8 % | 15 % | 1,68 $ | 0,26 $ | 0,32 $ |
| 2025 | 1,22 Mrd. | 73,4 Mio. | 0,46 $ | 159,72 Mio. | 0,6 Mio · 0,4 % | 1,6 Mio · 1 % | 64,8 % | 6 % | 1,61 $ | 0,26 $ | 0,32 $ |
| 2024 | 1,16 Mrd. | 168,11 Mio. | 1,05 $ | 160,77 Mio. | 0,5 Mio · 0,3 % | 1,6 Mio · 1 % | 66,4 % | 14,5 % | 1,47 $ | 0,24 $ | 0,32 $ |
| 2023 | 1,14 Mrd. | 285,26 Mio. | 1,76 $ | 161,86 Mio. | 0,5 Mio · 0,3 % | 2,8 Mio · 1,7 % | 67,7 % | 25,1 % | 1,34 $ | 0,24 $ | 0,32 $ |
| 2022 | 1,11 Mrd. | 272,05 Mio. | 1,66 $ | 164,11 Mio. | 0,6 Mio · 0,4 % | — | 68,4 % | 24,6 % | 1,71 $ | 0,26 $ | 0,32 $ |
| 2021 | 931,03 Mio. | 140,41 Mio. | 0,87 $ | 161,93 Mio. | 0,7 Mio · 0,4 % | — | 68 % | 15,1 % | 1,90 $ | 0,30 $ | 0,32 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 321,19 Mio. | 54,62 Mio. | 0,35 $ | 157,03 Mio. | 65,8 % | 17 % | 0,55 $ |
| Q1 2026 | 311,42 Mio. | 51,05 Mio. | 0,32 $ | 157,4 Mio. | 66,9 % | 16,4 % | 0,49 $ |
| Q4 2025 | 295,88 Mio. | 38,01 Mio. | 0,24 $ | 157 Mio. | 64,7 % | 12,9 % | 0,49 $ |
| Q3 2025 | 286,56 Mio. | 38,19 Mio. | 0,24 $ | 156,36 Mio. | 65,7 % | 13,3 % | 0,14 $ |
| Q2 2025 | 316,97 Mio. | -17,68 Mio. | -0,11 $ | 155,76 Mio. | 62,7 % | -5,6 % | 0,59 $ |
| Q1 2025 | 316,18 Mio. | 22,59 Mio. | 0,14 $ | 158,94 Mio. | 67,9 % | 7,1 % | 0,20 $ |
| Q4 2024 | 297,03 Mio. | 34,89 Mio. | 0,22 $ | 160,63 Mio. | 65,3 % | 11,8 % | 0,48 $ |
| Q3 2024 | 289,46 Mio. | 33,6 Mio. | 0,21 $ | 161,12 Mio. | 63,2 % | 11,6 % | 0,34 $ |
Is Bio-Techne Stock Outperforming the Nasdaq?
Bio-Techne Shareholders Approve Takeover by Merck KGaA
3 Reasons to Sell TECH and 1 Stock to Buy Instead
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio Techne (TECH) And The Valuation Case Behind Its Recent Rebound
Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing applications. Its portfolio supports workflows across basic research, translational science, and clinical decision-making, serving customers in academic laboratories, biotechnology and pharmaceutical development, and diagnostic settings. The company’s products include proteins, antibodies, immunoassays, ELISA kits, molecular diagnostics, spatial biology tools, and specialized instruments used to detect, measure, and analyze biological activity. Bio-Techne also provides custom services such as antibody development, protein degradation solutions, gene engineering, and cell and gene therapy-related services. Through its Protein Sciences and Diagnostics and Spatial Biology businesses, Bio-Techne plays an important role in enabling scientific discovery, biomarker analysis, and laboratory testing across the global healthcare and life sciences market.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest TECH und jede andere Aktie unbegrenzt.